This Month in JNM

December 3, 2018

Discussions with Leaders:
JNM editor-in-chief Johannes Czernin launches a series of interviews with leaders in nuclear and molecular imaging and therapy with a conversation with Sam Gambhir. Page 1783

End of the LNT era? Doss looks briefly at the strength of evidence against the linear no-threshold model, the weakness of evidence supporting it, and whether advisory and regulatory bodies may be compelled to reject the model. Page 1786

Nuclear neuroimaging in SAD: Doruyter and colleagues review the role of nuclear imaging techniques in investigating resting regional neural activity in social anxiety disorder and at potential future applications in novel molecular targets. Page 1794

Radiological treatment of liver tumors: Cornelis and Solomon offer an educational overview of the most common techniques in image-guided procedures, evidence supporting current indications in liver tumors, and upcoming developments in combination with temperature-sensitive liposomes or immunotherapy. Page 1801

¹⁸F-Alfatide II PET in breast cancer: Wu and colleagues investigate the utility of this PET tracer based on dimeric arginine-glycine-aspartate peptide for identifying suspected primary breast cancer and compare results with those from ¹⁸F-FDG PET/CT. Page 1809

Dose reduction in PET/MR imaging: Sah and colleagues determine the level of clinically acceptable ¹⁸F-FDG dose reduction in time-of-flight PET/MR imaging in patients with histologically proven breast cancer. Page 1817

¹⁸F-FDG and ¹⁸F-NaF in bone-dominant MBC: Peterson and colleagues prospectively test ¹⁸F-FDG PET and ¹⁸F-NaF PET to predict time to skeletal-related events, time to progression, and overall survival in patients with bone-dominant metastatic breast cancer. Page 1823

PET/CT interobserver agreement in DLBCL: Burggraaff and colleagues assess interobserver agreement between interim PET and end-of-chemotherapy PET, using the Deauville score in first-line diffuse large B-cell lymphoma patients. Page 1831

⁶⁸Ga PET/CT and lymphatic drainage: Doughton and colleagues report on a pilot study of the feasibility, safety, and utility of a novel ⁶⁸Ga-nanocolloid radiotracer with PET/CT lymphoscintigraphy for identification of sentinel lymph nodes in patients with prostate cancer. Page 1837

Tumor- and immune-cell–targeted therapy: Choi and colleagues detail efficacy studies of ¹⁷⁷Lu-LLP2A, alone and with immune checkpoint inhibitors in B16F10 tumor–bearing mice, and describe the potential for targeting both tumor cells and immune cells in metastatic melanoma. Page 1843

Featured Clinical Investigation Article:
Whole-body ⁶⁸Ga-PSMA-11 PET/MR: Thalgott and colleagues explore the diagnostic potential of this 1-stop-shop prostate-specific membrane antigen ligand in PET/MR imaging and compare it with preoperative staging nomograms in patients with high-risk prostate cancer. Page 1850

PSMA-RADS 1.0 interobserver agreement: Werner and colleagues determine interobserver agreement for applying this recently introduced standardized reporting and data system for prostate-specific membrane antigen–targeted PET imaging studies in interpretation of ¹⁸F-DCFPyL PET in typical clinical workflow. Page 1857

MSG, kidneys, and salivary glands: Rousseau and colleagues evaluate the ability of monosodium glutamate to reduce the salivary and kidney uptake of a prostate-specific membrane antigen radioligand (⁶⁸Ga-PSMA-11) without affecting tumor uptake. Page 1865

Featured Article of the Month:
Three novel tau radiopharmaceuticals: Wong and colleagues describe the first assessment in humans of ¹¹C-RO-963, ¹¹C-RO-643, and ¹⁸F-RO-948 for PET tau imaging in patients with amyloid-positive Alzheimer disease and younger controls. Page 1869

¹⁸F-RO-948 for tau quantification: Kuwabara and colleagues report on the kinetics of a novel radioligand, ¹⁸F-RO-948, and its use in PET identification of tau positivity in individual patients with mild Alzheimer disease. Page 1877

Featured Basic Science Article:
Immuno-PET after BACE-1 inhibition: Meier and colleagues investigate a novel PET radioligand based on an antibody directed toward soluble aggregates of Aβ for use in detecting changes in Aβ levels during Alzheimer disease progression and after β-secretase inhibitor treatment. Page 1885

Noninvasive imaging of CAR T cells: Larimer offers perspective on imaging approaches to monitoring treatment with chimeric antigen receptor T cells in patients with non-Hodgkin or diffuse large B-cell lymphoma and preview a related article in this issue of JNM. Page 1892

DOTA antibody for T cell tracking: Krebs and colleagues determine whether DOTA antibody reporter 1 can be expressed on lymphocytes and used as a reporter gene as well as a suicide gene for therapy of immune-related adverse effects. Page 1894

In ovo imaging with routine scanners: Freesmeyer and colleagues verify the feasibility of using ostrich eggs for imaging on clinical PET/CT scanners, without the need for dedicated equipment for small-sized eggs. Page 1901

PET radioligands for COX-1 and COX-2: Kim and colleagues assess whether newly developed PET radioligands ¹¹C-PS13 and ¹¹C-MC1 can image constitutive levels of cyclooxygenase-1 and -2, respectively, in rhesus monkeys. Page 1907

PCa PET/MR including bone: Elschot and colleagues evaluate the effects of including bone in Dixon-based attenuation correction for ¹⁸F-fluciclovine PET/MR imaging in primary and recurrent prostate cancer. Page 1913